Join to View Full Profile
505 Parnassus AveRm 987San Francisco, CA 94143
Phone+1 415-476-1528
Fax+1 415-502-1976
Dr. Keenan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bridget Keenan is an oncologist based in San Francisco, California. She completed her Internal Medicine residency and Hematology/Oncology Fellowship at the University of California San Francisco and is a graduate of the Johns Hopkins University School of Medicine. Dr. Keenan has published research in various prestigious journals including Cell Reports, The Oncologist, Cancer Research Communications, and JAMA Oncology, having been cited multiple times by her peers. Her research topics range from gender equity in medicine to cancer immunotherapy and gastrointestinal malignancies. She is the Principal Investigator of early phase clinical trials studying immunotherapy for advanced or metastatic cancer, and she is the co-director of the UCSF Cancer Immunotherapy Program.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 2017
Johns Hopkins University School of MedicineClass of 2015
Certifications & Licensure
CA State Medical License 2016 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Start of enrollment: 2020 May 29
Roles: Principal Investigator, Contact
- A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer Start of enrollment: 2021 Mar 08
Roles: Principal Investigator
Publications & Presentations
PubMed
- TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.Ruth Plummer, Mikael H Sodergren, Rose Hodgson, Bríd M Ryan, Nina Raulf
Cell Reports. Medicine. 2025-03-26 - A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.Andrew H Ko, Joseph Chao, Marcus S Noel, Veena Shankaran, Davendra Sohal
Cancer Research Communications. 2025-02-01 - 1 citationsOral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.Chitra Priya Emperumal, Alessandro Villa, Caleb Hwang, David Oh, Lawrence Fong
Clinical Genitourinary Cancer. 2024-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
